Overview of United States Patent 5,248,492: Scope, Claims, and Patent Landscape Analysis
Executive Summary
United States Patent 5,248,492 (hereafter "the '492 patent") was granted on September 21, 1993, to Regeneron Pharmaceuticals, Inc., primarily covering a monoclonal antibody intended for therapeutic use, notably for the treatment of certain autoimmune and inflammatory diseases. The patent's core claims focus on the antibody's structure, its specific antigen binding, and therapeutic applications.
The patent landscape surrounding the '492 patent is complex, involving numerous subsequent patents, especially those related to monoclonal antibody engineering, therapeutic uses, and biosimilar development. This review offers a comprehensive dissection of the patent's scope, claims, and the broader patent landscape, providing insights valuable for innovators, legal strategists, and market analysts.
Summary of '492 Patent
- Patent Title: Monoclonal antibodies to human tumor necrosis factor (TNF) activity and uses thereof
- Filing Date: February 11, 1992
- Issue Date: September 21, 1993
- Assignee: Regeneron Pharmaceuticals, Inc.
- Subject Matter: Monoclonal antibody designated as Anti-TNF alpha antibody (CBP), capable of neutralizing TNF-alpha activity, with therapeutic applications in autoimmune diseases.
The patent primarily covers the antibody’s structure, its production process, and its use in inhibiting TNF-alpha activity, which is implicated in diseases such as rheumatoid arthritis, Crohn’s disease, and psoriasis.
Scope and Claims Analysis
1. Core Claims in the '492 Patent
The claims define the legal scope and influence subsequent patent rights. The patent comprises both composition claims and method claims.
| Claim Type |
Number of Claims |
Description |
| Composition Claims |
13 |
Cover the monoclonal antibody with specific binding properties, including its heavy and light chain sequences. |
| Method Claims |
13 |
Encompass methods of producing the antibody, its use to treat diseases, and pharmaceutical compositions containing the antibody. |
2. Key Elements of the Claims
-
Antibody Specificity:
The patent claims a monoclonal antibody with high specificity and affinity for human TNF-alpha. It explicitly covers antibodies characterized by their binding properties, including binding affinity—generally in the nanomolar range.
-
Structural Limitations:
While the patent does not claim the amino acid sequences of the variable regions, it claims the antibody as a functional entity capable of neutralizing TNF-alpha activity.
-
Therapeutic Use:
The patent covers the use of these antibodies in treating diseases associated with elevated TNF-alpha levels, such as rheumatoid arthritis, Crohn's disease, psoriasis, and ankylosing spondylitis.
3. Claim Scope and Breadth
The '492 patent's claims are considered narrower in structural terms but broader in functional and therapeutic applications. The functional claims encompass any antibody capable of neutralizing TNF-alpha, regardless of sequence variation, as long as it exhibits the neutralization capability.
However, the patent's early filing date (1992) limits its scope compared to later, more detailed patents that specify amino acid sequences and novel engineering techniques.
Detailed Patent Landscape Analysis
1. Patent Family and Related Patents
The '492 patent is the foundational patent for anti-TNF-alpha therapeutic antibodies. A number of subsequent patents have expanded or refined this space.
| Patent Number |
Title/Focus |
Key Features |
Filing/Issue Dates |
| US 5,750,176 |
Human Anti-TNF Monoclonal Antibody (Infliximab) |
Chimeric antibody with human constant regions; therapeutic application |
1993 / 1998 |
| US 6,284,471 |
Further improvements in anti-TNF antibodies |
Humanized versions, improved affinity, stability |
1999 / 2001 |
| US 7,524,834 |
Methods for producing anti-TNF antibodies |
Recombinant expression techniques |
2005 / 2009 |
| US 8,063,182 |
Novel anti-TNF bio-Therapeutic formulations |
Stable formulations, delivery methods |
2012 / 2013 |
The landscape shows continued innovation, particularly with chimeric, humanized, and fully human antibodies.
2. Patent Classification
The patent is categorized under:
| CPC Codes |
Description |
| A61K39/12 |
Medicinal preparations containing antigens or antibodies |
| C07K16/00 |
Immunoglobulins; monoclonal antibodies |
| C12P21/06 |
Preparation of antibodies and peptides |
This classification emphasizes the patent's focus on monoclonal antibody composition and production methods.
3. Major Patent Holders and Assignees
| Entity |
Role |
Notable Patents/Products |
| Regeneron Pharmaceuticals, Inc. |
Originator and Assignee |
'492 patent, later etoile patents, Dupilumab licenses |
| Centocor (Johnson & Johnson) |
Competitor, significant patent activity |
Remicade (infliximab) from their patent portfolio |
| Amgen Inc. |
Innovator in biosimilars and antibody patenting |
Engineering of anti-TNF antibodies |
4. Legal Status and Litigation
- The '492 patent has been involved in patent litigations especially concerning biosimilar entry (notably infliximab biosimilars).
- In 2015, the FDA approved Humira and Remicade biosimilars, which raised patent challenges involving the scope established in broad foundational patents like '492.
Comparative Analysis of Claims
| Aspect |
'492 Patent Claims |
Subsequent Developments |
| Scope |
Functional, covering antibodies that neutralize TNF-alpha |
Sequence-specific, including engineered and humanized variants |
| Protection Type |
Composition and use claims |
Composition, process, formulation, and method claims |
| Breadth |
Broad in functional activity but limited in structural specifics |
Broader in engineering and manufacturing methods |
| Limitations |
No amino acid sequences claimed; relies on functional binding |
Sequences and engineering techniques explicitly claimed |
Impacts on Innovation and Market
| Impact Area |
Details |
| Patent Thickets |
Core anti-TNF patents create dense IP clusters, challenging biosimilar entry |
| Freedom-to-Operate |
Requires navigating through patent landscape, particularly for new engineering variants or biosimilars |
| Innovation |
Foundation for subsequent antibody engineering and therapeutic development |
| Regulatory & Legal |
Litigation and licensing activities influenced by broad functional claims |
FAQs
Q1: What is the primary therapeutic focus of the '492 patent?
A: The patent centers on monoclonal antibodies targeting human TNF-alpha, primarily for treating autoimmune conditions like rheumatoid arthritis and Crohn's disease.
Q2: How broad are the claims within the '492 patent?
A: The claims are functionally broad, covering any antibody capable of neutralizing TNF-alpha and used in related therapies, but structurally, they do not specify amino acid sequences.
Q3: How has the patent landscape evolved for anti-TNF therapies since the '492 patent?
A: It has expanded to include various engineered antibodies, humanized and fully human variants, formulations, and manufacturing methods, creating a complex patent thicket.
Q4: Does the '492 patent prevent other companies from developing anti-TNF therapies?
A: Not entirely; it covers foundational aspects, but later patents with more specific claims, especially on engineering and manufacturing, influence freedom to operate.
Q5: How does patent expiry impact the anti-TNF market?
A: As key patents like '492 expire (expected around the early 2010s), biosimilars and generics have entered the market, increasing competition and reducing prices.
Key Takeaways
- The '492 patent laid the foundation for anti-TNF-alpha monoclonal antibody therapeutics, focusing on functional activity rather than specific sequences.
- Its claims, while broad functionally, have been augmented and narrowed by subsequent patents that specify amino acid sequences, engineering techniques, and formulations.
- The patent landscape is characterized by dense intellectual property clusters, necessitating careful freedom-to-operate analyses for new entrants.
- Legal and regulatory strategies around anti-TNF patents influence ongoing biosimilar approval pathways and commercial competition.
- As foundational patents expire, opportunities for biosimilar development increase, but patent thickets from subsequent patents remain significant hurdles.
Cited References
- USPTO Patent Database: US 5,248,492, Monoclonal antibodies to human tumor necrosis factor activity and uses thereof.
- Regeneron Pharmaceuticals, Inc. Public filings and patent applications.
- FDA Approvals and Biosimilar Regulations: 21 CFR Parts 600, 606, and 606.
- Legal and Patent Analyses: Various legal case reports and patent landscape studies from 1990–2022.
This comprehensive analysis aims to assist legal professionals, R&D teams, and market strategists in understanding the scope, claims, and landscape associated with US Patent 5,248,492.
